Drug Profile

HOB 047

Alternative Names: GPR-6277; HD 6277; HDNO-1605; HOB-047

Latest Information Update: 27 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hyundai Pharmaceutical
Class Antihyperglycaemics; Small molecules
Mechanism of Action FFAR1 protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Type 2 diabetes mellitus

Most Recent Events

12 Dec 2024 Hyundai Pharminitiates enrolment in a phase II trial for Type 2 diabetes mellitus in South korea (NCT06647550)
18 Oct 2024 Hyundai Pharm plans phase II HDNO-1605 trial in Type 2 diabetes mellitus (PO) (NCT06647550)
21 Jun 2024 Efficacy and adverse events data from the phase II trial in Type 2 diabetes mellitus presented at 84th Annual Scientific Sessions of the American Diabetes Association (ADA-2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com